LDOC1 depletion enhanced the activation of EGFR, HER2, HER3, and AXL, and LDOC1 downregulation was strongly correlated with poor overall survival in patients with EGFRM advanced NSCLC who received gefitinib. This evidence concerns the gene EGFR and non-small cell lung carcinoma.